Difference between revisions of "Workshop on Clinical Trial Ontology"
| Line 1: | Line 1: | ||
== General Information == | == General Information == | ||
| − | The National Center for Biomedical Ontology will host a two-day workshop focused on the Ontology of Clinical Trials. The workshop will take place in May 2007 | + | The National Center for Biomedical Ontology will host a two-day workshop focused on the Ontology of Clinical Trials. The workshop will take place in May 2007 at a venue to be determined. |
== Aim of the workshop == | == Aim of the workshop == | ||
Revision as of 23:53, 19 June 2006
General Information
The National Center for Biomedical Ontology will host a two-day workshop focused on the Ontology of Clinical Trials. The workshop will take place in May 2007 at a venue to be determined.
Aim of the workshop
The aim of the workshop is to foster the creation of a reference ontology (high-quality controlled structured vocabulary) for clinical trial annotation. The ontology should provide a definitions for terms like: cohort, randomization, placebo, response, efficacy, control, protocol, null hypothesis, control, confidence intervals, etc., including also major relevant statistical terms.
The proposed CTO should:
(1) fully and faithfully capture the types of entities and relationships involved in clinical trials of any experimental design
(2) comprehend all the terms needed for the task of meta-analysis of clinical trials
(3) support trial bank interoperation
(4) form an integral part of a more comprehensive investigation ontology, including also the Functional Genomics Investigation Ontology, which should form part of the OBO Foundry.
The purpose of the meeting is to bring together representatives of the major groups involved in clinical trial informatics, design, execution, analysis and standardization in order to approve an initial draft of the CTO and create a strategy for its further development and testing.
Further topics to be addressed include:
i. The relation between CTO and data-model-oriented initiatives (HL7, CDISC, BRIDG, caBIG).
ii. The relation between CTO and a drug (trial) ontology
iii. The relation between CTO and an epidemiology study ontology
iv. The proper treatment of types (surgical intervention, tumor, human being) and instances (Jane's oophorectomy, John's tumor, Fritz) in ontologies and related artifacts.
v. The relation between CTO, Trialbank, and OBD.
Agenda
Participation
Requests for participation are welcome. Please send a brief statement of your expertise to Barry Smith.
Participants (First Tentative List)
Russ Altman -- Stanford University
Carol Bean -- NCRR/NIH
Werner Ceusters -- NCBO, University at Buffalo
Chris Chute -- NCBO, Mayo Clinic, Rochester, MN
Lindsay Cowell -- Duke University
Peter Good -- NHGRI/NIH
Norbert Graf -- ACGT, Homburg, Germany
Ted Grasela -- Cognigen Corporation, Amherst, NY
Suzanna Lewis -- NCBO, Berkeley
Chris Mungall -- Howard Hughes Institute
Mark Musen -- NCBO, Stanford University
Fabian Neuhaus -– NCBO, University at Buffalo
Ricardo Pietrobon -- Duke University
Philippe Rocca-Serra -- EBI, Hinxton, Cambridge
Nigam Shah -– NCBO, Stanford Medical Informatics
Susanna Sansone -- EBI, Hinxton, Cambridge
Ida Sim -- NCBO, University of California at San Francisco Medical Center
Barry Smith -– NCBO, University at Buffalo
Samson Tu -- Stanford University
Still more tentative: BRIDG: ? Doug Fridsma, ? Joyce Niland CDISC: ? Becky Kush HL7: ? Lakshmi Grama caBIG: ? NIH Roadmap: ? Stuart Speedie (U. Minn) AMIA CT WG: ? Michael Kahn, Charlie Barr, AMIA KR WG: ? Columbia group on Clinical Trials Informatics